Myeloma Current Events | Myeloma News
|
|
|
Sort By:
Page Views | Date |
Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma
Mayo Clinic Cancer Center researchers have found that chaetocin, a by-product of a common wood mold, has promise as a new anti-myeloma agent. view more (2007-04-16)
New study suggests possible genetic links between environmental toxins and multiple myeloma
The International Myeloma Foundation (IMF)-supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians-today said newly published data may provide a possible genetic link between environmental toxins and bone disease in multiple myeloma. view more (2009-08-13)
Multiple myeloma clinical trial closes early
Mayo Clinic Cancer Center announced today that a multiple myeloma clinical trial has shown a significant improvement in survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone. view more (2007-04-05)
Oral Drug Sets a New Survival Standard for Bone Marrow Cancer
Findings from two large, international clinical trials show "unprecedented" survival for patients with multiple myeloma, a blood cancer that occurs in the blood-making cells of bone marrow. view more (2007-11-26)
3-drug combination 'extremely promising' as first-line therapy for multiple myeloma
A new combination of bortezomib (Velcade) and two other drugs is showing a very high response rate in patients newly diagnosed with multiple myeloma, a team headed by Dana-Farber Cancer Institute investigators reported at the annual meeting of the American Society of Hematology. view more (2007-12-12)
Keeping cancer at bay: Long-term therapy in the fight against multiple myeloma
There is no known cure for multiple myeloma, so its diagnosis means high-dose chemotherapy followed by repeated treatments with each relapse of the cancer - a watch and wait approach. view more (2006-11-06)
Studies at cancer conference show new therapies changing outlook for blood cancer patients
The International Myeloma Foundation (IMF) - conducting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today noted that multiple studies presented at the 2006 Annual Meeting of the American Society of Hematology (ASH) illustrate the breadth of the gains being made in the... view more... (2006-12-11)
Obesity found to be a risk factor for multiple myeloma
An obese person is more likely than a lean person to develop multiple myeloma, according to researchers from Brigham and Women's Hospital, Harvard Medical School, and Harvard School of Public Health. view more (2007-07-20)
Stem cells make bone marrow cancer resistant to treatment
Scientists at the Johns Hopkins Kimmel Cancer Center say they have evidence that cancer stem cells for multiple myeloma share many properties with normal stem cells and have multiple ways of resisting chemotherapy and other treatments. view more (2008-01-14)
Mayo Clinic research shows promise for myeloma patients
Mayo Clinic Cancer Center investigators report that combination therapy with lenalidomide (RevlimidTM) and dexamethasone (combination is called Rev/Dex) looks like a breakthrough treatment for multiple myeloma. view more (2005-09-02)
An advanced genetic diagnostic method for multiple myeloma
A researcher at the University of Navarra, Borja Sáez Ochoa, has proposed a new genetic diagnostic method for multiple myeloma (MM), a type of bone marrow cancer, which permits the detection of this disease in earlier stages. view more (2006-09-12)
Emory researchers identify signaling protein for multiple myeloma
Researchers at Emory University's Winship Cancer Institute are the first to discover a mechanism that plays a critical role in the multiple myeloma cell cycle and survival. view more (2007-09-11)
Gene profiling can single out the worst cases of multiple myeloma and guide therapy
Multiple myeloma patients vary widely in how they respond to treatment, but now researchers at the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences have identified a small subset of genes whose activity could predict high-risk cases and potentially guide therapy in the future. view more (2007-09-19)
Drug combination slows progression of treatment resistant bone marrow cancer
Combining a newly formulated drug with one that is already a standard treatment slows the progression of multiple myeloma, an advanced cancer of the bone marrow cells. view more (2006-12-13)
Race a factor in receiving transplant treatment for bone marrow cancer but does not affect outcomes
A new study by researchers at The Medical College of Wisconsin Cancer Center Milwaukee, has found that African Americans and whites have identical survival rates after undergoing autologous (self donor) bone marrow transplant treatment for a common cancer of the bone marrow (multiple myeloma). view more (2008-12-09)
Thalidomide treatment proves better than conventional chemotherapy for multiple myeloma
When people hear "thalidomide," many think "birth defects," however, evidence has come to light that this once-banned drug can be used as a potent anti-cancer treatment. In a new study, researchers from the University of Bologna, Italy, demonstrate that Thal-Dex (thalidomide used in combination with dexamethasone) is more... view more... (2005-06-21)
Promising results from 2 trials highlighting pomalidomide presented at ASH
Celgene International Sarl (Nasdaq: CELG) today announced that its next IMiDs compound, pomalidomide, has shown promising activity with manageable safety and tolerability for the treatment of relapsed/refractory multiple myeloma (MM) and myelofibrosis. view more (2008-12-11)
Scientists discover new genetic subtypes of common blood cancer
Scientists at Dana-Farber Cancer Institute and collaborators have identified four distinct genetic subtypes of multiple myeloma, a deadly blood cancer, that have different prognoses and might be treated most effectively with drugs specifically targeted to those subtypes. view more (2006-04-11)
Genome changes tracked during multiple myeloma initiation, progression and treatment
Scientists have made significant progress toward elucidating key genetic events associated with the development and progression of multiple myeloma (MM), an incurable malignancy that is the second most common cancer of the blood. view more (2006-04-11)
Analysis shows revlimid plus dexamethasone increases overall survival in multiple myeloma patients
Celgene International Sarl (NASDAQ: CELG) announced that data from a landmark analysis of patients with relapsed/refractory multiple myeloma found that continuous treatment with REVLIMID (lenalidomide) in combination with dexamethasone after achieving best response resulted in significantly longer overall survival and increased time to disease... view more... (2008-12-11)
|
|
|
|
Sort By:
Page Views | Date |
|
